These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 24805358

  • 21. The Role of Selection in the Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation.
    Klil-Drori A, Azoulay L.
    JAMA Intern Med; 2015 Jul; 175(7):1243-4. PubMed ID: 26146918
    [No Abstract] [Full Text] [Related]

  • 22. Plasma dabigatran activity one week after discontinuation despite normal renal function.
    Thachil J, Pike G, Keighley-Jones L, Nash MJ.
    Am J Med; 2013 Aug; 126(8):e5-6. PubMed ID: 23800582
    [No Abstract] [Full Text] [Related]

  • 23. Atrial fibrillation: Risk of bleeding with dabigatran versus warfarin particularly high in CKD.
    Carney EF.
    Nat Rev Nephrol; 2015 Jan; 11(1):3. PubMed ID: 25421829
    [No Abstract] [Full Text] [Related]

  • 24. Dabigatran overdose secondary to acute kidney injury and amiodarone use.
    Fountzilas C, George J, Levine R.
    N Z Med J; 2013 Mar 01; 126(1370):110-2. PubMed ID: 23474519
    [Abstract] [Full Text] [Related]

  • 25. [Dabigatran and risk of bleeding].
    Hasler S.
    Praxis (Bern 1994); 2015 Jan 28; 104(3):157-8. PubMed ID: 25626386
    [No Abstract] [Full Text] [Related]

  • 26. One-Year Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation: Placing Real-World Results Into Perspective.
    Miyares MA.
    JAMA Intern Med; 2015 Jul 28; 175(7):1242-3. PubMed ID: 26146916
    [No Abstract] [Full Text] [Related]

  • 27. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.
    Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, Ezekowitz MD, Yusuf S.
    Stroke; 2012 Jun 28; 43(6):1511-7. PubMed ID: 22492518
    [Abstract] [Full Text] [Related]

  • 28. Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data.
    Hernandez I, Zhang Y.
    JAMA Intern Med; 2015 Jul 28; 175(7):1245-7. PubMed ID: 26146922
    [No Abstract] [Full Text] [Related]

  • 29. A Methodological Appraisal of Recent Real-World Data Publications on Dabigatran.
    Zint K, Kreuzer J.
    JAMA Intern Med; 2015 Jul 28; 175(7):1244. PubMed ID: 26146919
    [No Abstract] [Full Text] [Related]

  • 30. Bleeding in Patients of African Ancestry Using Dabigatran: A Potential Effect of Creatine Kinase.
    Horjus DL, van Montfrans GA, Brewster LM.
    JAMA Intern Med; 2015 Jul 28; 175(7):1243. PubMed ID: 26146917
    [No Abstract] [Full Text] [Related]

  • 31. Gastrointestinal bleeding under dabigatran.
    Stöllberger C, Lindner K, Finsterer J.
    J Postgrad Med; 2014 Jul 28; 60(2):192-3. PubMed ID: 24823522
    [Abstract] [Full Text] [Related]

  • 32. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H.
    Circ Cardiovasc Qual Outcomes; 2013 Sep 01; 6(5):567-74. PubMed ID: 23922182
    [Abstract] [Full Text] [Related]

  • 33. [Exfoliative esophagitis while taking dabigatran].
    Scheppach W, Meesmann M.
    Dtsch Med Wochenschr; 2015 Apr 01; 140(7):515-8. PubMed ID: 25826037
    [Abstract] [Full Text] [Related]

  • 34. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
    Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjøth F, Rosenzweig M, Lip GY.
    Am J Med; 2014 Jul 01; 127(7):650-656.e5. PubMed ID: 24530792
    [Abstract] [Full Text] [Related]

  • 35. Pitfalls of the interpretation of myocardial infarction data in patients on dabigatran treatment.
    Pontillo D, Patruno N.
    J Cardiovasc Med (Hagerstown); 2015 Feb 01; 16(2):142. PubMed ID: 25539158
    [No Abstract] [Full Text] [Related]

  • 36. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L, Chen C, White J.
    Consult Pharm; 2014 Mar 01; 29(3):169-78. PubMed ID: 24589766
    [Abstract] [Full Text] [Related]

  • 37. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
    Koziński M, Obońska K, Kubica A, Navarese EP, Kubica J.
    Kardiol Pol; 2012 Mar 01; 70(10):1053-60. PubMed ID: 23080100
    [No Abstract] [Full Text] [Related]

  • 38. Dabigatran for stroke prevention in atrial fibrillation.
    Hohnloser SH, Diener HC.
    Hamostaseologie; 2012 Mar 01; 32(3):216-20. PubMed ID: 22739760
    [Abstract] [Full Text] [Related]

  • 39. [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
    Szapary L, Fehér G, Bosnyák E, Deli G, Csécsei P.
    Ideggyogy Sz; 2013 May 30; 66(5-6):165-74. PubMed ID: 23909016
    [Abstract] [Full Text] [Related]

  • 40. Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants.
    Rockey DC.
    Nat Rev Gastroenterol Hepatol; 2015 Mar 30; 12(3):131-2. PubMed ID: 25601661
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.